Mirum Pharmaceuticals (MIRM) Climbed, So What Is Behind The Move?

Mirum Pharmaceuticals (MIRM) is back in focus after fresh data from its PROGRESS trial reported positive 24 week outcomes for ATEBRIOZ in children aged 6 to under 12 with fibrodysplasia ossificans progressiva.

Investors have reacted quickly to the trial update, with a 1 day share price return of 2.75% lifting Mirum Pharmaceuticals to US$85.56. However, the stock is still down 24.01% over 90 days and has a 201.06% total shareholder return over three years, which points to strong long term momentum despite recent volatility.

Spot emerging rare-disease momentum plays by scanning the 21 high quality undiscovered gems that pair meaningful pipelines with solid underlying fundamentals.

Mirum Pharmaceuticals now sits at an interesting crossroads, where fresh trial success and a sharp three year run meet a 24% pullback. Is this week’s bounce just sentiment, or closer to what the business is worth?

Most Popular Narrative: 44% Undervalued

Mirum Pharmaceuticals closed at $85.56, while the most widely followed narrative framework places fair value at $153.07 using a 7.67% discount rate. That gap sets a high bar for future execution and turns every clinical update, including PROGRESS and EXPAND, into a valuation catalyst.

Multiple late-stage pipeline catalysts, including three pivotal study readouts (VISTAS, VANTAGE, EXPAND) over the next 24 months and the initiation of the Phase II Fragile X study, set the stage for further product label expansions and new indication launches, underpinning future revenue diversification and potential earnings acceleration.

See why 12 investors see Mirum Pharmaceuticals as 44% undervalued.

On this narrative, Mirum Pharmaceuticals screens as materially undervalued, with the fair value estimate sitting 44.1% above the current market level. The view ties that gap to late stage study milestones, Livmarli label expansion work and broader rare disease exposure, while still acknowledging concentration risk and funding needs.

Result: Fair Value of $153.07 (UNDERVALUED)

Still, the Mirum Pharmaceuticals story can change quickly if Livmarli concentration becomes a drag or if volixibat’s PSC path faces further regulatory delays.

Find out about the key risks to this Mirum Pharmaceuticals narrative.

Next Steps

Mixed sentiment surrounds Mirum Pharmaceuticals so far. If you want a clearer perspective and to act before sentiment shifts again, start by weighing the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Mirum Pharmaceuticals?

You do not need to stop at Mirum Pharmaceuticals. Broaden your watchlist with other focused ideas that match your risk, income, and quality preferences.

• Target higher potential upside by scanning the 29 high quality undervalued stocks that combine solid fundamentals with pricing that may not fully reflect their underlying strength.
• Strengthen your defensive side by reviewing the 30 resilient stocks with low risk scores that prioritize resilient balance sheets and steadier return profiles when markets become more volatile.
• Look for emerging companies with room for change by working through the 7 elite penny stocks with strong financials where smaller businesses can be evaluated more closely.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com